AZD 9838
Alternative Names: AZD-9838Latest Information Update: 20 Dec 2023
At a glance
- Originator AstraZeneca
- Class COVID-19 vaccines; RNA vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 27 Nov 2023 Phase-I clinical trials in COVID-2019 infections (Prevention) in USA (IM) (NCT06147063)
- 27 Nov 2023 AstraZeneca plans the phase I ARTEMIS-C trial for COVID-2019 infections (Prevention) in USA (IM, Injection), in December 2023 (NCT06147063)
- 27 Nov 2023 Preclinical trials in COVID-2019 infections (Prevention) in United Kingdom (IM), prior to November 2023 (AstraZeneca pipeline, November 2023)